The Latin America, Middle East and Africa T-Cell therapy Market would witness market growth of 22.7% CAGR during the forecast period (2023-2030).
Hematological malignancies can be effectively treated using cellular therapy. In Europe, more than 40,000 allogeneic and autologous hematopoietic stem cell transplantation (HSCTs) are carried out each year. A novel T-cell therapy called chimeric antigen receptor-T (CAR-T) cells have been approved outside of clinical trials as of 2017. The antitumor activity of CAR-T cells is incredibly strong. Patients receive chemotherapy before receiving CAR-T cells, which reduces immunosuppressive cells and promotes CAR-T cell expansion.
The prevalence of cancer is rising rapidly in children as well. Acute lymphoblastic leukemia (ALL), the most prevalent malignancy in children, was a major focus of the original development of CAR T-cell treatments. While intense chemotherapy can cure more than 80% of kids with ALL that develops in B cells, there are no standard treatments for those whose tumors recur after a stem cell transplant or chemotherapy. For instance, a study team under the direction of the NCI recently published data on the long-term outcomes of children with relapsed ALL who had received CAR T-cells as part of a clinical trial.
In the Middle East, multiple myeloma (MM) is the most prevalent hematological cancer. The highest incidence of MM and related morbidity and mortality are found in Qatar and the UAE. The resource-strapped nations in this region are being severely burdened by increasing cancer morbidity rates. Several authorities in this region have admitted that handling hematological malignancies might be challenging. The development of new therapies like T-cells has considerably improved the prospects for cancer patients. Since cancer, in particular, hematological malignancies, are becoming more common in this region, the demand for T-cell therapies has increased significantly, which is advancing the regional market.
The Brazil market dominated the LAMEA T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $178.2 million by 2030. The Argentina market is estimated to grow at a CAGR of 23.3% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 22.3% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide T-Cell therapy Market is Projected to reach USD 9.2 Billion by 2030, at a CAGR of 17.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA T-Cell therapy Market, by End User
1.4.2 LAMEA T-Cell therapy Market, by Indication
1.4.3 LAMEA T-Cell therapy Market, by Therapy Type
1.4.4 LAMEA T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. LAMEA T-Cell therapy Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Cancer Treatment Centers Market by Country
Chapter 5. LAMEA T-Cell therapy Market by Indication
5.1 LAMEA Lymphoma Market by Country
5.2 LAMEA Acute Lymphocytic Leukemia Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA T-Cell therapy Market by Therapy Type
6.1 LAMEA CAR T-Cell Therapy Market by Country
6.2 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 LAMEA Axicabtagene Ciloleucel Market by Country
6.2.2 LAMEA Tisagenlecleucel Market by Country
6.2.3 LAMEA Brexucabtagene Autoleucel Market by Country
6.2.4 LAMEA Others Market by Country
6.3 LAMEA T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. LAMEA T-Cell therapy Market by Country
7.1 Brazil T-Cell therapy Market
7.1.1 Brazil T-Cell therapy Market by End User
7.1.2 Brazil T-Cell therapy Market by Indication
7.1.3 Brazil T-Cell therapy Market by Therapy Type
7.1.3.1 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 Argentina T-Cell therapy Market
7.2.1 Argentina T-Cell therapy Market by End User
7.2.2 Argentina T-Cell therapy Market by Indication
7.2.3 Argentina T-Cell therapy Market by Therapy Type
7.2.3.1 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 UAE T-Cell therapy Market
7.3.1 UAE T-Cell therapy Market by End User
7.3.2 UAE T-Cell therapy Market by Indication
7.3.3 UAE T-Cell therapy Market by Therapy Type
7.3.3.1 UAE T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Saudi Arabia T-Cell therapy Market
7.4.1 Saudi Arabia T-Cell therapy Market by End User
7.4.2 Saudi Arabia T-Cell therapy Market by Indication
7.4.3 Saudi Arabia T-Cell therapy Market by Therapy Type
7.4.3.1 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type
7.5 South Africa T-Cell therapy Market
7.5.1 South Africa T-Cell therapy Market by End User
7.5.2 South Africa T-Cell therapy Market by Indication
7.5.3 South Africa T-Cell therapy Market by Therapy Type
7.5.3.1 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type
7.6 Nigeria T-Cell therapy Market
7.6.1 Nigeria T-Cell therapy Market by End User
7.6.2 Nigeria T-Cell therapy Market by Indication
7.6.3 Nigeria T-Cell therapy Market by Therapy Type
7.6.3.1 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type
7.7 Rest of LAMEA T-Cell therapy Market
7.7.1 Rest of LAMEA T-Cell therapy Market by End User
7.7.2 Rest of LAMEA T-Cell therapy Market by Indication
7.7.3 Rest of LAMEA T-Cell therapy Market by Therapy Type
7.7.3.1 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
TABLE 1 LAMEA T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 2 LAMEA T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– T-Cell therapy Market
TABLE 4 Product Launches And Product Expansions– T-Cell therapy Market
TABLE 5 Acquisition and Mergers– T-Cell therapy Market
TABLE 6 Geographical Expansions – T-Cell therapy Market
TABLE 7 Trials and Approvals – T-Cell therapy Market
TABLE 8 LAMEA T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 9 LAMEA T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 10 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 12 LAMEA Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
TABLE 14 LAMEA T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 15 LAMEA T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 16 LAMEA Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 17 LAMEA Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 18 LAMEA Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 19 LAMEA Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
TABLE 20 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 21 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 22 LAMEA T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 23 LAMEA T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 24 LAMEA CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
TABLE 25 LAMEA CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
TABLE 26 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 27 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 28 LAMEA Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
TABLE 29 LAMEA Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
TABLE 30 LAMEA Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
TABLE 31 LAMEA Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
TABLE 32 LAMEA Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
TABLE 33 LAMEA Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
TABLE 34 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 35 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 36 LAMEA T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
TABLE 37 LAMEA T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
TABLE 38 LAMEA T-Cell therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 LAMEA T-Cell therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 Brazil T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 41 Brazil T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 42 Brazil T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 43 Brazil T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 44 Brazil T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 45 Brazil T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 46 Brazil T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 47 Brazil T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 48 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 49 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 50 Argentina T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 51 Argentina T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 52 Argentina T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 53 Argentina T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 54 Argentina T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 55 Argentina T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 56 Argentina T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 57 Argentina T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 58 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 59 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 60 UAE T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 61 UAE T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 62 UAE T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 63 UAE T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 64 UAE T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 65 UAE T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 66 UAE T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 67 UAE T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 68 UAE T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 69 UAE T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 70 Saudi Arabia T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 71 Saudi Arabia T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 72 Saudi Arabia T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 73 Saudi Arabia T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 74 Saudi Arabia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 75 Saudi Arabia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 76 Saudi Arabia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 77 Saudi Arabia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 78 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 79 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 80 South Africa T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 81 South Africa T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 82 South Africa T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 83 South Africa T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 84 South Africa T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 85 South Africa T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 86 South Africa T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 87 South Africa T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 88 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 89 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 90 Nigeria T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 91 Nigeria T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 92 Nigeria T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 93 Nigeria T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 94 Nigeria T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 95 Nigeria T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 96 Nigeria T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 97 Nigeria T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 98 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 99 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 100 Rest of LAMEA T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 101 Rest of LAMEA T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 102 Rest of LAMEA T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 103 Rest of LAMEA T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 104 Rest of LAMEA T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 105 Rest of LAMEA T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 106 Rest of LAMEA T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 107 Rest of LAMEA T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 108 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 109 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 110 key Information – Merck KGaA
TABLE 111 Key information –Johnson & Johnson
TABLE 112 Key information – AbbVie, Inc.
TABLE 113 Key Information – Gilead Sciences, Inc.
TABLE 114 Key Information – Amgen, Inc.
TABLE 115 Key Information – Novartis AG
TABLE 116 Key Information – Sorrento Therapeutics, Inc.
TABLE 117 Key Information – Bristol Myers Squibb Company
TABLE 118 Key Information – Pfizer, Inc.
TABLE 119 Key Information – Immunocore Holdings plc
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
FIG 5 LAMEA T-Cell therapy Market share by End User, 2022
FIG 6 LAMEA T-Cell therapy Market share by End User, 2030
FIG 7 LAMEA T-Cell therapy Market by End User, 2019 - 2030, USD Million
FIG 8 LAMEA T-Cell therapy Market share by Indication, 2022
FIG 9 LAMEA T-Cell therapy Market share by Indication, 2030
FIG 10 LAMEA T-Cell therapy Market by Indication, 2019 - 2030, USD Million
FIG 11 LAMEA T-Cell therapy Market share by Therapy Type, 2022
FIG 12 LAMEA T-Cell therapy Market share by Therapy Type, 2030
FIG 13 LAMEA T-Cell therapy Market by Therapy Type, 2019 - 2030, USD Million
FIG 14 LAMEA T-Cell therapy Market share by Country, 2022
FIG 15 LAMEA T-Cell therapy Market share by Country, 2030
FIG 16 LAMEA T-Cell therapy Market by Country, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: Merck KGaA
FIG 18 Recent strategies and developments: Johnson & Johnson
FIG 19 SWOT analysis: Johnson & Johnson
FIG 20 Recent strategies and developments: Gilead Sciences, Inc.
FIG 21 Recent strategies and developments: Amgen, Inc.
FIG 22 Recent strategies and developments: Novartis AG
FIG 23 Recent strategies and developments: Sorrento Therapeutics, Inc.
FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Recent strategies and developments: Immunocore Holdings plc